Beiersdorf Ag

Turbine Raises $25 Million Series B to Expand AI-Powered Virtual Biology Platform into Immunology

- Turbine secured $25 million in Series B funding led by Interactive Venture Partners to expand its AI-powered virtual cell platform beyond oncology into immunology applications. - The company announced its first immunology-focused partnership with a top 10 pharmaceutical company to model immune cell behavior and identify novel therapeutic combinations. - Turbine's virtual assays have supported more than 30 discovery programs to date, enabling researchers to test millions of hypotheses at computational speed and scale. - The funding will support expansion of Turbine's Virtual Lab platform to cover additional assays across discovery and translational medicine workflows.